Fibrosis and carcinoid syndrome: from causation to future therapy (Q34658528)

3 August 2017

1 reference

title

Fibrosis and carcinoid syndrome: from causation to future therapy (English)

1 reference

3 August 2017

1 reference

Ashley B Grossman

1 reference

3 August 2017

Maralyn Druce

1 reference

3 August 2017

Andrea Rockall

series ordinal

1 reference

3 August 2017

publication date

1 May 2009

1 reference

Nature Reviews Endocrinology

3 August 2017

published in

1 reference

3 August 2017

1 reference

3 August 2017

1 reference

3 August 2017

page(s)

276-283

1 reference

Siegfried Oberndorfer: origins and perspectives of carcinoid tumors

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Current status of gastrointestinal carcinoids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors – Well-Differentiated Jejunal-Ileal Tumor/Carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Carcinoid tumors and fibrosis: an association with no explanation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Florid Angiogenesis in Mucosa Surrounding an Ileal Carcinoid Tumor Expressing Transforming Growth Factor-α

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

A case of ureteric obstruction, retroperitoneal fibrosis, and carcinoid tumour

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

[Edema caused by retroperitoneal and tricuspid fibrosis with sclerodermatous cutaneous involvement disclosing carcinoid tumor. Apropos of a case and review of the literature]

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Ileal carcinoid tumor complicated by retroperitoneal fibrosis and a prolactinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Retroperitoneal fibrosis and nonmalignant ileal carcinoid.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Lung fibrosis in carcinoid syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Synchronous double primary lung cancers of squamous and neuroendocrine type associated with cryptogenic fibrosing alveolitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Neuroendocrine cell hyperplasia and obliterative bronchiolitis in patients with peripheral carcinoid tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Lower extremity vasospasm associated with ischemic neuropathy, dermal fibrosis, and digital gangrene in a patient with carcinoid syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Cutaneous manifestations of the malignant carcinoid syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Scleroderma and the carcinoid syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

The carcinoid endocardial plaque; an ultrastructural study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Analysis of 150 patients with carcinoid syndrome seen in a single year at one institution in the first decade of the twenty-first century

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

31 March 2020

Carcinoid heart disease

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Carcinoid heart disease: diagnosis by two-dimensional echocardiography

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Valvular heart disease and the use of dopamine agonists for Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

MRI of carcinoid tumors: spectrum of appearances in the gastrointestinal tract and liver

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Calcification and fibrosis in mesenteric carcinoid tumor: CT findings and pathologic correlation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

CT Findings in Sclerosing Mesenteritis (Panniculitis): Spectrum of Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

From the archives of the AFIP: benign fibrous tumors and tumorlike lesions of the mesentery: radiologic-pathologic correlation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Role of serotonin in the hepato-gastroIntestinal tract: an old molecule for new perspectives.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

A review of central 5-HT receptors and their function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Ras involvement in signal transduction by the serotonin 5-HT2B receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

5-hydroxytryptamine 2B receptor regulates cell-cycle progression: cross-talk with tyrosine kinase pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Methysergide-induced heart disease: a case of multivalvular and myocardial fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Valvular heart disease associated with fenfluramine-phentermine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

An investigation of the serotonergic effects of fenfluramine, dexfenfluramine and dexnorfenfluramine using platelets as neuronal models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Long-term serotonin administration induces heart valve disease in rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

A mouse model of carcinoid syndrome and heart disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Regulation of collagen synthesis by inhibitory Smad7 in cardiac myofibroblasts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Serotonin mechanisms in heart valve disease I: serotonin-induced up-regulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Factors associated with progression of carcinoid heart disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Substance P and related peptides in porcine cortex: whole tissue and nuclear localization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

CTGF, intestinal stellate cells and carcinoid fibrogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Treatment of advanced carcinoid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Method for dissection of mesenteric metastases in mid-gut carcinoid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Intraperitoneal cisplatin with systemic thiosulfate protection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Carcinoid syndrome and serotonin: therapeutic effects of ketanserin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Ondansetron in carcinoid syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Long-term serotonin effects in the rat are prevented by terguride.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Terguride--a new dopamine agonist drug: a comparison of its neuroendocrine and side effect profile with bromocriptine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.51

Retroperitoneal fibrosis caused by carcinoid tumour

31 March 2020

1 reference

12 December 2020

Carcinoid tumors of the gastrointestinal tract

1 reference

12 December 2020

Inhibitory effects of ranitidine on flushing and serum serotonin concentrations in carcinoid syndrome

1 reference

12 December 2020

Midgut carcinoid tumors: CT findings and biochemical profiles

1 reference

12 December 2020

Carcinoid tumor of the small intestine: MDCT findings with pathologic correlation

1 reference

12 December 2020

Serotonin: a mediator of the brain-gut connection

1 reference

12 December 2020

Retroperitoneal fibrosis

1 reference

12 December 2020

Pleural involvement in the carcinoid syndrome

1 reference

12 December 2020

Involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2009.51

1 reference

3 August 2017

1 reference